Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2019

View Archived Issues

Gorilla virus makes stealth vaccine vector

Results from first clinical study evaluating KB-195 in patients with urea cycle disorders

Akouos reveals lead program for sensorineural hearing loss

Armata developing AP-PA02 targeting P. aeruginosa to treat respiratory infections

A silica cage ensures thermal stability of tuberculosis vaccine candidates without refrigeration

Eisai and Biogen decide to discontinue phase III MISSION AD program of elenbecestat

Recruitment ongoing in phase I study of DFP-14927

Replimune and Regeneron initiate phase II study of cemiplimab in cutaneous squamous cell carcinoma

Mutations in the PTCD3 gene identified as a novel cause of Leigh syndrome

Design of novel zebrafish models of cystinosis

Siponimod shows efficacy in combined toxic and inflammatory animal model of multiple sclerosis

NTP-42 alone and combined with sildenafil alleviates experimental pulmonary arterial hypertension

New biomarkers for NSCLC identified

Interrupting obesity-associated breast cancer progression

Incyte divulges new MAP4K1 inhibitors

New genes linked to mitral valve prolapse

Ono Pharmaceutical patents lysophospholipid S1P5 receptor agonists

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

Universita di Pisa identifies SIRT1 activators

FDA clears initiation of phase I trial of oral foralumab

Southern Research Institute discovers NF-kappaB activators

FDA and EMA offer Auris Medical guidance on phase II/III trial with Keyzilen

Phase III CANDOR study of daratumumab in multiple myeloma meets primary endpoint

Oncotartis conducts first-in-human study of OT-82 in relapsed or refractory lymphoma

Bayer launches first-in-human study of BAY-2416964 in advanced cancer

Model of sleep-disordered breathing may clarify associated disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...